Avalo Therapeutics appoints Jennifer Riley as Chief Strategy Officer; grants 150k stock option

Avalo Therapeutics, Inc.

Jennifer Riley appointed Chief Strategy Officer effective Jan 1, 2025; oversees corporate strategy and pipeline planning.
Base salary $450,000; discretionary annual bonus target up to 40% of base salary.
Received inducement stock option to purchase 150,000 shares, vesting over 4 years with 12-month cliff.
Severance includes 9 months base salary (12 months if termination within 6 months after Change in Control) and full option vesting.
Company advancing AVTX-009 (anti-IL-1β mAb) in LOTUS Phase 2 trial for hidradenitis suppurativa.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jennifer Riley

Chief Strategy Officer

AVTX · Avalo Therapeutics, Inc.

Effective: 2025-01-01
Filed: January 2, 2025, 6:59 PM ET

On January 2, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jennifer Riley was appointed as Chief Strategy Officer at Avalo Therapeutics, Inc..

Action: appointed
Role: Chief Strategy Officer

Exact text from the filing

On January 2, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025.

View on SEC.gov

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-25-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.